However, the successful implementation of precision medicine in pediatric gliomas with BRAF mutations requires addressing ethical and economic considerations, such as equitable access to genetic testing and targeted therapies, and evaluating the cost-effectiveness of these advanced treatment modalities. This evidence concerns the gene BRAF and glioma.